Halozyme Therapeutics, Inc. (HALO)
| Previous Close | 40.86 |
| Open | 41.10 |
| Bid | 41.35 x 100 |
| Ask | 41.54 x 100 |
| Day's Range | 40.87 - 41.65 |
| 52 Week Range | 29.85 - 45.00 |
| Volume | |
| Avg. Volume | 991,724 |
| Market Cap | 5.265B |
| Beta (5Y Monthly) | 1.25 |
| PE Ratio (TTM) | 19.73 |
| EPS (TTM) | 2.10 |
| Earnings Date | May 07, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 51.11 |
ZacksHalozyme Therapeutics (HALO) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates
Beyond analysts' top -and-bottom-line estimates for Halozyme Therapeutics (HALO), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.
Insider MonkeyHow Novo-Catalent Deal Affects Halozyme (HALO)?
Laughing Water Capital, an investment management company, released its first-quarter 2024 investor letter. A copy of the same can be downloaded here. In the first quarter, investment in the fund returned 8.4% after all fees and expenses compared to 10.6% and 5.2% returns for the SP500TR and R2000 during the quarter, respectively. In addition, you […]
ZacksHalozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy?
Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
